Evaluation of Different Dose Escalation Regimens for NNC0519-0130 in Participants With Overweight and Obesity
Latest Information Update: 11 Dec 2024
Price :
$35 *
At a glance
- Drugs NNC 0519 0130 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 11 Dec 2024 New trial record